Glioblastoma Multiforme (GBM) Treatment Market Size Forecasted To Achieve $4.1 Billion By 2029 With Steady Growth

The Glioblastoma Multiforme (GBM) Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Glioblastoma Multiforme (GBM) Treatment Market Size Expected to Be by 2034?
In recent times, the market size for the treatment of glioblastoma multiforme (GBM) has experienced significant growth. It is projected to increase from $2.48 billion in 2024 to $2.74 billion in 2025, with a compound annual growth rate (CAGR) of 10.2%. The increase in growth during the past period can be connected to a boost in incidence and prevalence, developments in diagnostic technologies, funding for clinical trials and research, collaborations and partnerships, and an enhanced comprehension of tumor biology.

The market size for the treatment of Glioblastoma Multiforme (GBM) is anticipated to experience a swift expansion in the upcoming years, reaching a value of $4.1 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 10.6%. This growth during the forecast period is likely due to the advent of immunotherapies, advancements in precision medicine, increased understanding of genetic markers, heightened patient advocacy and awareness, as well as government assistance for rare diseases. Key trends for the forecast period encompass the exploration of combination therapies, the incorporation of artificial intelligence in diagnosis and therapeutic planning, increased utilization of immunotherapeutic approaches, and the evolution of medical tools and equipment.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8803

What Are the Emerging Segments Within the Glioblastoma Multiforme (GBM) Treatment Market?
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented -

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

What Long-Term Drivers Are Shaping Glioblastoma Multiforme (GBM) Treatment Market Trends?
Anticipated growth of the glioblastoma multiforme (GBM) treatment market is being driven by a rise in brain disorders. These disorders, which involve unusual activity in the brain, spinal cord, and body's nerves, are becoming more widespread due to factors such as an elderly population, weakened immunity, over-diagnosis, ionizing radiation, and air pollution. Among these disorders is glioblastoma multiforme (GBM), the treatment for which remains a priority to maintain good health. A 2022 report from the American Cancer Society, a voluntary health organization focused on cancer elimination in the US, revealed that approximately 25,050 malignant brain or spinal cord tumors were identified in the US. Thus, the rising prevalence of brain disorders is contributing to the expansion of the GBM treatment market.

Who Are the Top Competitors in Key Glioblastoma Multiforme (GBM) Treatment Market Segments?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord HealTH*Care Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

What Glioblastoma Multiforme (GBM) Treatment Market Trends Are Gaining Traction Across Different Segments?
Top firms active in the market are intent on pioneering novel portable and wearable devices to maintain their competitive edge. With an objective to offer improved functionality, ease, and comfort, these advancements meet the escalating demand for accessible and efficacious healTH*Care services. For instance, Novocure, an oncology firm based in Jersey, in 2023, introduced Optune Gio, an FDA-approved wearable and movable treatment system for patients newly diagnosed with glioblastoma (GBM). This device uses Tumor Treating Fields (TTFields), alternating electric fields designed to interfere with cancer cell division, potentially prolonging the patient's life. With a weight of just 2.7 pounds, Optune Gio is designed for the comfort of the patient, enabling them to use it during everyday activities.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Which Regions Are Becoming Hubs for Glioblastoma Multiforme (GBM) Treatment Market Innovation?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Glioblastoma Multiforme (GBM) Treatment Market?
2. What is the CAGR expected in the Glioblastoma Multiforme (GBM) Treatment Market?
3. What Are the Key Innovations Transforming the Glioblastoma Multiforme (GBM) Treatment Industry?
4. Which Region Is Leading the Glioblastoma Multiforme (GBM) Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.